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The challenge involved in integrating unit operations for continuous bioprocessing is a significant impediment to 
implementation of the technology in the industry. The benefit of continuous bioprocessing can be better 
understood when the components of the technology are analyzed under multiple factors including modalities, 
protein quality attributes and stability, specific productivity and overall cost-benefit of implementation and 
operation of the technology. Contract Development and Manufacturing Organizations (CDMO) need to provide a 
portfolio of offerings that cover the needs of diverse groups and process needs. For example, processes with 
lower productivity and unstable molecules can benefit from a perfusion system while more stable molecules with 
high productivity may need to focus on the benefits of a continuous capture to address a potential bottleneck on 
the downstream.  
 
In this work, we present Catalent’s road map and rationale of the step-wise approach we are using toward the 
implementation of continuous bioprocessing. Our approach will facilitate the integration of the appropriate 
technology components tailored for each process in a timely and cost-effective manner. Modeling and 
simulation data will be presented to support the soundness of the approach using selected stages in a typical 
process for the production of monoclonal antibodies.  
 
As an example of the optimization of independent components of 
the technology, we will present results from experimental studies 
developed at bench and pilot scale. Figure 1 shows the results 
obtained when process parameters in the bioreactor were 
manipulated to achieve different steady states while maintaining 
titer and product quality for a production perfusion bioreactor.  
 
Additional studies at bench and pilot scale will be presented to 
demonstrate proof of concept of other components including N-1 
perfusion and continuous capture.  
 
The results are allocated to present a combination of scenarios 
that will guide the use of specific and combined components of 









Figure 1 – Optimization of Steady State 
conditions for increased productivity in a 
perfusion bioreactor 
